Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type … – Nasdaq
|
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type …
Nasdaq The initiation of this natural history study brings us one step closer to our goal of making a CRISPR-based medicine available to people with significant vision loss caused by LCA10," said Gerry Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine. |
